Skip to Content
Cancer Therapy Evaluation Program (CTEP)
Last Updated: 01/08/15

Jeff Moscow, MD

Jeff Moscow, MD

Medical Officer

Jeffrey A. Moscow, MD, joined the Investigational Drug Branch in January, 2014, after serving part-time in IDB since August, 2012. Prior to joining CTEP, he was Children’s Miracle Network Professor of Pediatrics, Chief of Pediatric Hematology-Oncology, Vice Chair of Pediatrics, and co-leader of the Experimental Therapeutics Program of the Markey Cancer Center, all at the University of Kentucky. His portfolio includes erlotinib, lapatanib, AZD 9291, CO-1686, trebananib, ch14.18, and CDX-011. Dr. Moscow has also taken a lead role in the re-design of the CTEP Phase 2 component of the Early Therapeutics Clinical Trials Network (ETCTN) and is slated to become its program director. In addition, Dr. Moscow has a laboratory research program in the Urologic Oncology Branch that is focused on targeting thiamine-dependent enzymes for cancer therapy.

Contact Information:
National Cancer Institute
9609 Medical Center Dr., MSC 9739
For USPS: Bethesda, MD 20892-9739
For Express and Courier: Rockville, MD 20850
Phone: 240-276-6565
Fax: 240-276-7894

About the Branch Chief

James Zwiebel, MD James Zwiebel received the MD degree from the Mount Sinai School of Medicine, where he also completed his residency training in internal medicine. Following a clinical fellowship in hematology and oncology at the George Washington University Medical Center and research fellowships at both the National Cancer Institute and the National Heart Lung and Blood Institute, he continued his laboratory work on cancer gene therapy as a member of the faculty at Lombardi Cancer Center of the Georgetown University Medical Center, where he also practiced hematology and oncology. More…